Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03439254
Registration number
NCT03439254
Ethics application status
Date submitted
14/02/2018
Date registered
20/02/2018
Date last updated
23/10/2023
Titles & IDs
Public title
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Query!
Scientific title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Query!
Secondary ID [1]
0
0
747-304
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REVERSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Compensated Cirrhosis
0
0
Query!
Nonalcoholic Steatohepatitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Obeticholic acid (10 mg)
Treatment: Drugs - Obeticholic acid (10 mg to 25 mg)
Treatment: Drugs - Placebo
Experimental: Obeticholic Acid (OCA) 10 mg - 10 mg OCA for up to 18 months
Experimental: Obeticholic Acid (OCA) 10 mg to 25 mg - 10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
Placebo comparator: Placebo - Placebo for up to 18 months
Treatment: Drugs: Obeticholic acid (10 mg)
Tablets administered orally once daily.
Treatment: Drugs: Obeticholic acid (10 mg to 25 mg)
Tablets administered orally once daily.
Treatment: Drugs: Placebo
Tablets administered orally once daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)
Query!
Assessment method [1]
0
0
Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=\<5% to 3=\>66%),lobular inflammation(0=no foci to 3=\>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment
Query!
Timepoint [1]
0
0
Up to 18 months
Query!
Primary outcome [2]
0
0
OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
Query!
Timepoint [2]
0
0
Up to 12 months
Query!
Primary outcome [3]
0
0
OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)
Query!
Assessment method [3]
0
0
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Query!
Timepoint [3]
0
0
Baseline and up to Month 12
Query!
Primary outcome [4]
0
0
OLE Phase: Fibrosis-4 (FIB-4) at Baseline
Query!
Assessment method [4]
0
0
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[Units per Liter {U/L}\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
Query!
Timepoint [4]
0
0
Baseline (Day 1)
Query!
Primary outcome [5]
0
0
OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline
Query!
Assessment method [5]
0
0
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; = 7.7 - \< 9.8: Moderate fibrosis; = 9.8 - \< 11.3: Severe fibrosis; = 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
Query!
Timepoint [5]
0
0
Baseline (Day 1)
Query!
Primary outcome [6]
0
0
OLE Phase: Number of Participants Reporting All-cause Mortality
Query!
Assessment method [6]
0
0
All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented
Query!
Timepoint [6]
0
0
Up to Month 12
Query!
Primary outcome [7]
0
0
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death
Query!
Assessment method [7]
0
0
Adjudication was performed under the review of Hepatic Safety Adjudication Committee (HSAC) of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for the following is presented: Ascites (secondary to cirrhosis and requiring medical intervention), Hepatocellular carcinoma (HCC) and non-liver related death.
Query!
Timepoint [7]
0
0
Up to 12 months
Query!
Primary outcome [8]
0
0
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score
Query!
Assessment method [8]
0
0
The Child-Pugh classification was a scoring system used for the classification of the severity of cirrhosis. It included three continuous variables (bilirubin, albumin, and international normalized ratio) and two discrete variables (ascites and encephalopathy). Each variable was scored 1-3 with 3 indicating most severe derangement. The determination of Child-Pugh score ranged from 5 to 15. The higher the score, the sicker the participant. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for worsening of Child-Pugh score is presented.
Query!
Timepoint [8]
0
0
Up to 12 months
Query!
Primary outcome [9]
0
0
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score =15
Query!
Assessment method [9]
0
0
MELD was a scoring system for assessing the severity of chronic liver disease and to assess prognosis and suitability for liver transplantation. It uses the participant's values for total bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. MELD score ranges from 6 (less ill) to 40 (gravely ill) with scores and mortality probability being: Score 40=71.3% mortality; Scores 30-39=52.6% mortality; Scores 20-29=19.6% mortality; Scores10-19=6.0% mortality; Score 9 or less=1.9% mortality. Higher scores indicated greater disease severity. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for MELD score =15 is presented.
Query!
Timepoint [9]
0
0
Up to 12 months
Query!
Secondary outcome [1]
0
0
DB Phase: Change From Baseline to Month 18 in LSM
Query!
Assessment method [1]
0
0
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Query!
Timepoint [1]
0
0
Baseline and up to Month 18
Query!
Secondary outcome [2]
0
0
DB Phase: FIB-4 at Baseline
Query!
Assessment method [2]
0
0
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
Query!
Timepoint [2]
0
0
Baseline (Day 1)
Query!
Secondary outcome [3]
0
0
DB Phase: ELF at Baseline
Query!
Assessment method [3]
0
0
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; = 7.7 - \< 9.8: Moderate fibrosis; = 9.8 - \< 11.3: Severe fibrosis; = 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
Query!
Timepoint [3]
0
0
Baseline (Day 1)
Query!
Eligibility
Key inclusion criteria
Key inclusion criteria:
1. Subjects with a confirmed diagnosis of NASH and a fibrosis score of 4 based upon the NASH CRN scoring system determined by central reading
Key exclusion criteria:
1. Current or past history of a clinically evident hepatic decompensation event, such as ascites, hepatic encephalopathy (HE), or variceal bleeding
2. Current or past history of CP score =7 points
3. Model for End-stage Liver Disease (MELD) score > 12
4. ALT = 5 X ULN
5. Calculated creatinine clearance <60mL/min using Cockcroft-Gault method
6. Hemoglobin A1c (HbA1c) = 9.5 %
7. Evidence of other known forms of chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)
8. History of liver transplant, or current placement on a liver transplant list
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/08/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/09/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
919
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Nepean Blue Mountains Local Health District, Nepean Hospital - Kingswood
Query!
Recruitment hospital [2]
0
0
Mater Misericordiae Limited - South Brisbane
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [4]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [5]
0
0
St Vincent's Hospital - Fitzroy
Query!
Recruitment hospital [6]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [7]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Minnesota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Mississippi
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nebraska
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nevada
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Jersey
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New York
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Rhode Island
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Dakota
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Tennessee
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Texas
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Vermont
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Virginia
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Washington
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Nova Scotia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Amiens
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Angers
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Clichy
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
La Tronche
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Lyon Cedex 04
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Nice
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Paris
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Rouen
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Strasbourg
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Toulouse
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Vandoeuvre-les-Nancy
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Villejuif
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Bayern
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Hessen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Rheinland-Pfalz
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Sachsen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Schleswig-Holstein
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Berlin
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hamburg
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Budapest
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Debrecen
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Gyula
Query!
Country [62]
0
0
New Zealand
Query!
State/province [62]
0
0
Auckland
Query!
Country [63]
0
0
New Zealand
Query!
State/province [63]
0
0
Christchurch
Query!
Country [64]
0
0
New Zealand
Query!
State/province [64]
0
0
Dunedin
Query!
Country [65]
0
0
New Zealand
Query!
State/province [65]
0
0
Wellington
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Czestochowa
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Gdansk
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Gdynia
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Katowice
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Poznan
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Warszawa
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Wroclaw
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Lódz
Query!
Country [74]
0
0
Puerto Rico
Query!
State/province [74]
0
0
San Juan
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Barcelona
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Madrid
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Santander
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Sevilla
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Valencia
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Kyiv
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Derbyshire
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
England
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Oxfordshire
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Tyne And Wear
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Intercept Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03439254
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/54/NCT03439254/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/54/NCT03439254/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03439254
Download to PDF